Skip to main content


Associated entities

Genomics is a cutting-edge technology field which is undergoing a dizzying rate of change and where the exchange of knowledge between initiatives that are part of international networks and ensure the knowledge that is ultimately applied to patients has maximum value and relevance is especially valuable. This is why NAGEN 1000 has already made very interesting connections with several prestigious entities of international renown and is working on establishing new links:


The Spanish Genomic Analysis Centre is part of the Spanish State’s Singular Scientific and Technical Infrastructures (ICTS). It is one of three platforms in Europe with the largest sequencing capacity and has ample experience in whole human genome sequencing (WGS). In addition, the CNAG-CRG has the support of the Spanish Supercomputing Centre (BSC-CNS), which provides it with all necessary IT&C infrastructures, and its own Bioinformatics Unit, which will render its services to the project and whose processes will be gradually transferred to the Consortium in order for them to be eventually introduced in the Community of Navarre. Moreover, the CNAG-CRG’s Director is a scientific advisor to the project.


The Clinical Bioinformatics Research Area (CBRA) of the Regional Government of Andalusia’s Progreso y Salud Foundation hosts the functional genomics node of the Spanish Bioinformatics Institute and the bioinformatics platform of the Centre for the Networked Biomedical Research of Rare Diseases.

Genomics England Ltd (GEL)

The 100,000 Genome Project, which is coordinated by the UK company GEL, is the largest whole human genome sequencing initiative in the world and is based on a joint strategy of clinical and genomic research that shares many goals and strategies with NAGEN 1000. The collaboration between both projects’ teams has been crucial to design the project that was finally submitted to this Call for Projects. Furthermore, there is a patent interest by both parties to expand cooperation between the projects as much as possible. In addition, the Director of the North East & North Cumbria NHS Genomic Medicine Centre (NENC GMC) – one of the thirteen genomic medicine centres that are taking part in the 100,000 Genomes Project – is a scientific advisor to the NAGEN 1000 Project.


The goals of the Carlos III Institute’s Centre for Networked Biomedical Research of Rare Diseases (CIBERER) are to investigate the biological causes of and mechanisms that trigger rare diseases, to develop new treatments, to improve medical procedures and to provide access to the diagnosis of these pathologies in our country. Since NAGEN 1000 is the biggest initiative for the research into the whole human genome of patients suffering from rare diseases that has ever been launched in Spain, both parties are obviously interested in working together to enlarge the body of scientific knowledge about these disorders at the national level. Furthermore, the Director of CIBERER’s Bioinformatics Platform is a scientific advisor to the project.